Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

2001 • 5,189 citations

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 • 4,320 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

2010 • 4,281 citations

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

2002 • 4,254 citations

EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 • 3,807 citations

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 • 3,500 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

2002 • 2,968 citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

2001 • 2,749 citations

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 • 2,500 citations

The development of androgen-independent prostate cancer

2001 • 2,285 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

2008 • 1,886 citations

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

2004 • 1,810 citations

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2004 • 1,785 citations

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

2002 • 1,771 citations

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

2009 • 1,655 citations

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

2008 • 1,606 citations

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

2010 • 1,604 citations

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

2007 • 1,571 citations

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2010 • 1,520 citations

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

2003 • 1,490 citations

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

2010 • 1,438 citations

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

2005 • 1,435 citations

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

2009 • 1,376 citations

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 • 1,349 citations

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

2008 • 1,306 citations

Tumor Self-Seeding by Circulating Cancer Cells

2009 • 1,274 citations

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

2009 • 1,262 citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

2010 • 1,218 citations

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

2010 • 1,163 citations

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

2009 • 1,159 citations

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

2008 • 1,027 citations

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

2010 • 1,007 citations

High-throughput oncogene mutation profiling in human cancer

2007 • 995 citations

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

2009 • 942 citations

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

2005 • 941 citations

BRAF Mutation in Papillary Thyroid Carcinoma

2003 • 915 citations

Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)

2001 • 868 citations

Dynamics of chronic myeloid leukaemia

2005 • 838 citations

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

2006 • 824 citations

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

2010 • 820 citations

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

2005 • 805 citations

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

2008 • 802 citations

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

2009 • 789 citations

Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells

2005 • 761 citations

Oncogene Addiction

2008 • 744 citations

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

2010 • 712 citations

Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy

2006 • 698 citations

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models withEGFRandERBB2Mutations that Are Resistant to Gefitinib

2007 • 688 citations

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

2008 • 688 citations

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

2002 • 675 citations

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

2007 • 627 citations

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

2003 • 624 citations

MEK1 mutations confer resistance to MEK and B-RAF inhibition

2009 • 622 citations

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

2008 • 606 citations

Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

2004 • 605 citations

Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome

2006 • 579 citations

Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome

2006 • 549 citations

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment

2002 • 534 citations

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

2008 • 524 citations

Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

2008 • 500 citations

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

2005 • 491 citations

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

2008 • 485 citations

Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study

2009 • 459 citations

Resistance to Trastuzumab in Breast Cancer

2009 • 451 citations

Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

2009 • 435 citations

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

2007 • 431 citations

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

2010 • 414 citations

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

2006 • 369 citations

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4

2009 • 350 citations

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

2010 • 340 citations

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

2010 • 339 citations

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

2002 • 321 citations

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

2010 • 316 citations

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

2010 • 313 citations

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

2009 • 304 citations

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

2009 • 304 citations

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

2009 • 296 citations

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

2008 • 286 citations

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

2008 • 274 citations

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

2005 • 263 citations

The cardiofaciocutaneous syndrome

2006 • 261 citations

Toward a Molecular Classification of Melanoma

2007 • 247 citations

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

2009 • 245 citations

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

2010 • 245 citations

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

2009 • 242 citations

Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance

2008 • 238 citations

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

2007 • 227 citations

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

2010 • 223 citations

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors

2009 • 217 citations

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

2009 • 213 citations

Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor

2005 • 211 citations

Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

2003 • 199 citations

The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

2008 • 196 citations

Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line

2007 • 193 citations

Prediction of Resistance to Small Molecule FLT3 Inhibitors

2004 • 172 citations

Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

2006 • 167 citations

Breast Cancer — Loss of PTEN Predicts Resistance to Treatment

2004 • 161 citations

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

2008 • 153 citations

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

2009 • 148 citations

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia

2003 • 129 citations

Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology

2009 • 125 citations

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

2002 • 119 citations

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors

2005 • 116 citations

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

2009 • 105 citations

The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.

2003 • 100 citations

Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists

2009 • 78 citations

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer

2010 • 73 citations

Resistance in the land of molecular cancer therapeutics

2002 • 68 citations

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

2008 • 67 citations

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

2005 • 66 citations

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia

2007 • 65 citations

Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naïve Malignant Pleural Mesothelioma

2008 • 48 citations

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

2009 • 45 citations

Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab

2010 • 44 citations

Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial

2008 • 37 citations

A phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of one line of chemotherapy (LUX-Lung 2)

2009 • 22 citations

Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases

2005 • 15 citations

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

2007 • 12 citations

Nilotinib - A novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond

2007 • 8 citations